AstraZeneca shares drop on rumored $160 billion mega-merger

Shares of Anglo-Swedish pharma giant AstraZeneca dropped notably following market rumors of a possible mega-merger with a major industry player. The reported deal valuation of around $160 billion drew skepticism from some investors, who question whether it adequately balances risk and reward for shareholders. Merger rumors in the pharmaceutical sector frequently trigger volatility in shares of both companies involved in a speculated transaction. The market's reaction also reflects broader concerns about the high cost of capital for large M&A deals in the current rate environment. Neither company has officially confirmed the talks, and investors are awaiting further statements.